Eicosapentaenoic and Docosahexaenoic Acids Differentially Alter Gut Microbiome and Reverse High-Fat Diet-Induced Insulin Resistance.

Pan Zhuang,Yu Zhang,Qiyang Shou,Haoyu Li,Ya'er Zhu,Lilin He,Jingnan Chen,Jingjing Jiao
DOI: https://doi.org/10.1002/mnfr.201900946
IF: 6.5749
2020-01-01
Molecular Nutrition & Food Research
Abstract:ScopeTo assess the individual effects of dietary eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on insulin resistance (IR), gut microbiome, and gut metabolites in high‐fat‐diet‐induced obese (DIO) mice.Methods and resultsDIO mice are fed an either high‐fat diet (HFD), EPA (1% w/w) enriched HFD, or DHA (1% wt/wt) enriched HFD for 15 weeks. Both EPA and DHA supplements reverse hyperglycemia and IR but do not affect body weight in DIO mice while DHA exhibits a more pronounced ameliorative effect in male mice. Both EPA‐ and DHA‐enriched Lactobacillus and short‐chain fatty acids (SCFAs)‐producing species from Lachnospiraceae while reduced lipopolysaccharide (LPS)‐producing Bilophila and Escherichia/Shigella. Compared with EPA, DHA‐supplemented mice have more abundant propionic/butyric acid‐producing bacteria, including Coprococcus, Butyricimonas synergistica, Bacteroides acidifaciens, and Intestinimonas, and less‐abundant LPS‐correlated species Streptococcus and p‐75‐a5. The shifts in gut microbiome co‐occurred with the changes in levels of propionic/butyric acid, circulating LPS, and serotonin. Additionally, EPA/DHA supplementation attenuates adipose inflammation with upregulated glucose transporter 4 and Akt phosphorylation, indicating the improvement of insulin signaling.ConclusionEPA and DHA differentially reverse IR and relieve adipose inflammation while modulating gut microbiome and SCFAs/LPS production, underscoring the gut‐adipose axis as a primary target of EPA/DHA.
What problem does this paper attempt to address?